Australia signs $1.7bn manufacturing agreements for COVID-19 vaccines

The Australian government has signed a $1.7 billion supply and production agreement with a number of pharmaceutical companies for two COVID-19 vaccines.

Under the agreement, the University of Oxford/AstraZeneca and the University of Queensland/CSL will provide more than 84.8 million vaccine doses for the Australian population, almost entirely manufactured in Melbourne, with early access to 3.8 million doses of the University of Oxford vaccine in January and February 2021.

Prime Minister Scott Morrison said both vaccines would need to be proven safe and effective, and meet all necessary regulatory requirements, prior to being made available to the public.

“Australians will gain free access to a COVID-19 vaccine in 2021 if trials prove successful,” the PrimeMinister said.

“By securing the production and supply agreements, Australians will be among the first in the world to receive a safe and effective vaccine, should it pass late stage testing.

“There are no guarantees that these vaccines will prove successful, however the agreement puts Australia at the top of the queue, if our medical experts give the vaccines the green light.”

The University of Oxford/AstraZeneca vaccine is world leading, having entered Phase three trials. To date it has generated strong immune responses, with no significant safety concerns.

The University of Queensland (UQ) vaccine has been developed in Australia by world class scientists and researchers, with support from the Australian Government.

UQ has recently announced that pre-clinical testing showed the vaccine is promising and already effective in animal models.

This production and supply agreement is part of the Australian Government’s COVID Vaccine and Treatment Strategy and was recommended by the expert advisory group –  COVID-19 Vaccine and Treatments for Australia – Science and Industry Technical Advisory Group.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Boehringer & Click to develop digital therapeutic for schizophrenia

Boehringer Ingelheim and Click Therapeutics will together develop and commercialise of a prescription-based digital therapeutic for schizophrenia. It will utilise cognitive and neurobehavioral mechanisms delivered...

Huadong Medicine & Exscientia to accelerate oncology drug discovery with AI

Exscientia, an AI drug discovery company, and Chinese pharma firm, Huadong Medicine, have partnered to accelerate the discovery of breakthrough small-molecule therapeutics targeted at...

Celltrion given the go-ahead for anti-COVID-19 antibody trial

Celltrion’s Investigational New Drug (IND) application for a Phase II/III pivotal clinical trial of CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate, has been approved...

Search for new cancer treatments get £8m genetic boost

Projects to find new treatments for cancer, using whole genome sequencing, have received a £8 million funding boost from UK Research and Innovation (UKRI). Despite...

Mylan acquiring Aspen’s European thrombosis business

Mylan is expanding its complex injectables offering and presence in hospitals with the €641.9 million acquisition of Aspen Pharmacare's thrombosis business in Europe. The portfolio...

Related news

Merck takes $1bn stake in Seattle Genetics as part of oncology collaboration

Merck is acquiring a $1 billion stake in Seattle Genetics has part of two new strategic oncology collaborations between the two companies. The companies will...

Boehringer & Click to develop digital therapeutic for schizophrenia

Boehringer Ingelheim and Click Therapeutics will together develop and commercialise of a prescription-based digital therapeutic for schizophrenia. It will utilise cognitive and neurobehavioral mechanisms delivered...

Huadong Medicine & Exscientia to accelerate oncology drug discovery with AI

Exscientia, an AI drug discovery company, and Chinese pharma firm, Huadong Medicine, have partnered to accelerate the discovery of breakthrough small-molecule therapeutics targeted at...

Celltrion given the go-ahead for anti-COVID-19 antibody trial

Celltrion’s Investigational New Drug (IND) application for a Phase II/III pivotal clinical trial of CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate, has been approved...